Cargando…

Retraction statement: Dai, Y., Xie, F. and Chen, Y. (2020), Reduced levels of miR‐485‐5p in HPV‐infected cervical cancer promote cell proliferation and enhance invasion ability. FEBS Open Bio, 10: 1348–1361.

https://doi.org/10.1002/2211-5463.12869 The above article, published online on 28 April 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the Editor‐in‐Chief, FEBS Press, and John Wiley and Sons Ltd. The retraction has been agreed following a...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392050/
https://www.ncbi.nlm.nih.gov/pubmed/37219053
http://dx.doi.org/10.1002/2211-5463.13622
Descripción
Sumario:https://doi.org/10.1002/2211-5463.12869 The above article, published online on 28 April 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the Editor‐in‐Chief, FEBS Press, and John Wiley and Sons Ltd. The retraction has been agreed following an investigation into concerns raised by a third party, which revealed inappropriate duplications between this and previously published articles [1–3]. Thus, the editors consider the conclusions of this manuscript substantially compromised. Reference 1 Guan L, Ji D, Liang N, Li S and Sun B (2018) Up‐regulation of miR‐10b‐3p promotes the progression of hepatocellular carcinoma cells via targeting CMTM5. J Cell Mol Med 22, 3434–3441.doi: 10.1111/jcmm.13620 2 Xu B, Xu T, Liu H, Min Q, Wang S and Song Q (2017) MiR‐490‐5p Suppresses Cell Proliferation and Invasion by Targeting BUB1 in Hepatocellular Carcinoma Cells. Pharmacology 100, 269–282.doi: 10.1159/000477667 3 Butz H, Szabó PM, Khella HW et al. (2015 May) miRNA‐target network reveals miR‐124as a key miRNA contributing to clear cell renal cell carcinoma aggressive behaviour by targeting CAV1 and FLOT1. Oncotarget 6 (14), 12543–12557.doi: 10.18632/oncotarget.3815 PMID: 26002553; PMCID: PMC4494957